

Epigenetics Drugs And Diagnostic Technologies Market anticipated to surpass \$53.345 billion by 2030 at a CAGR of 15.21%

The epigenetics drugs and diagnostic technologies market is anticipated to grow at a CAGR of 15.21% from US\$26.283 billion in 2025 to US\$53.345 billion by 2030.

NEW YORK, NY, UNITED STATES, April 22, 2025 /EINPresswire.com/ -- According to a new study published by Knowledge Sourcing Intelligence, the epigenetics drugs and diagnostic technologies market is projected to grow at a CAGR of 15.21% between 2025 and 2030 to reach US\$53.345 billion by 2030.



The global market for epigenetics drugs and diagnostic technologies is experiencing significant growth, providing hope for patients with various diseases and conditions.



The epigenetics drugs and diagnostic technologies market is anticipated to grow at a CAGR of 15.21% from US\$26.283 billion in 2025 to US\$53.345 billion by 2030."

Knowledge Sourcing Intelligence Epigenetics is the study of changes in gene expression that are not caused by changes in the DNA sequence. This field has gained significant attention in recent years due to its potential to treat a wide range of diseases, including cancer, neurological disorders, and autoimmune diseases. The increasing prevalence of these diseases, coupled with the growing understanding of epigenetic mechanisms, is driving the growth of the epigenetics drugs and diagnostic technologies market.

One of the key factors contributing to the growth of this market is the rising demand for <u>personalized medicine</u>.

Epigenetic drugs and diagnostic technologies allow for a more targeted and individualized

approach to treatment, leading to better outcomes for patients. Additionally, the increasing investments in research and development by <u>pharmaceutical</u> companies and government organizations are also fueling the market growth.

The market is also witnessing a surge in collaborations and partnerships between pharmaceutical companies and research institutions to develop new and innovative epigenetic drugs and diagnostic technologies. This is expected to further drive the market growth in the coming years.

The epigenetics drugs and diagnostic technologies market is poised for significant growth in the coming years, providing hope for patients and their families. With advancements in technology and increasing investments in research and development, the market is expected to continue its upward trajectory. This presents a promising opportunity for pharmaceutical companies and research institutions to collaborate and develop innovative treatments for various diseases and conditions.

Access sample report or view details: https://www.knowledge-sourcing.com/report/epigenetics-drugs-and-diagnostic-technologies-market

As a part of the report, the major players operating in the epigenetics drugs and diagnostic technologies market that have been covered are Roche Diagnostics, Thermo Fisher Scientific, Inc., Element Biosciences, Inc., Dovetail Genomics LLC., Abcam plc., Eisai Co., Ltd., Novartis AG, Cantata Bio, among others.

The market analytics report segments the epigenetics drugs and diagnostic technologies market as follows:

- By Drugs
- o Histone Deacetylase (HDAC) Inhibitors
- o DNA Methyltransferase (DNMT) Inhibitors
- o Others
- By Technology
- Reagents
- Kits
- o Chip Sequencing Kit
- o Whole Genomic Amplification Kit
- o Bisulfite Conversion Kit
- o RNA Sequencing Kit

- Instruments
- Services
- Others
- By Application
- Oncology
- Non-oncology
- o Inflammatory Diseases
- o Metabolic Diseases
- o Infectious Diseases
- o Cardiovascular Diseases
- o Others
- By Geography
- North America
- o USA
- o Canada
- o Mexico
- · South America
- o Brazil
- o Argentina
- o Rest of South America
- Europe
- o United Kingdom
- o Germany
- o France
- o Italy
- o Spain
- o Rest of Europe
- · Middle East and Africa
- o Saudi Arabia
- o UAE
- o Rest of the Middle East and Africa
- Asia Pacific

- o China
- o India
- o Japan
- o South Korea
- o Taiwan
- o Thailand
- o Indonesia
- o Rest of Asia-Pacific

Companies Profiled:

- Roche Diagnostics
- Thermo Fisher Scientific, Inc.
- Element Biosciences, Inc.
- Dovetail Genomics LLC.
- · Abcam plc.
- · Eisai Co., Ltd.
- Novartis AG
- · Cantata Bio
- · Illumina, Inc.
- Promega Corporation
- Merck KGaA

Reasons for Buying this Report:-

- Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub-segments.
- Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
- Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
- Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
- Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do Businesses use our Reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive

Intelligence

Report Coverage:

- Historical data from 2022 to 2024 & forecast data from 2025 to 2030
- Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
- Competitive Positioning, Strategies, and Market Share Analysis
- Revenue Growth and Forecast Assessment of segments and regions including countries
- Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Explore More Reports:

- Tissue Diagnostics Market: https://www.knowledge-sourcing.com/report/tissue-diagnostics-market
- Global Critical Care Diagnostics Market: https://www.knowledge-sourcing.com/report/global-critical-care-diagnostics-market
- Global Cancer Diagnostics Market: https://www.knowledge-sourcing.com/report/global-cancer-diagnostics-market
- Point of Care Diagnostic Market: https://www.knowledge-sourcing.com/report/point-of-care-diagnostic-market

About Us

Knowledge Sourcing Intelligence (KSI) is a market research and intelligence provider that uses a combination of quantitative and qualitative research techniques to deliver comprehensive, indepth insights to clients. Our approach to market research is centered around the concept of 'Knowledge Sourcing' - the process of gathering data and insights from multiple sources to create a comprehensive and well-rounded picture of the market. KSI's core services include market intelligence, competitive intelligence, customer intelligence, and product intelligence. KSI's approach to market research is designed to help clients make informed decisions, identify opportunities, and gain a better understanding of their target markets. By using a combination of primary and secondary research techniques, we provide clients with detailed insights into current market trends, customer profiles, competitor analysis, and product performance. KSI's market research and intelligence services enable clients to make informed decisions, develop strategic plans, and identify areas of opportunity.

Harsh Sharma Knowledge Sourcing Intelligence LLP +1 850-250-1698 info@knowledge-sourcing.com Visit us on social media:

Facebook X LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/805420297

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.